Search

Displaying results 4601 - 4610 of 4822 in total
  1. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  2. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on positi...

  3. Drug

    Octacosanol

    go.drugbank.com/drugs/DB11220
    InvestigationalNutraceutical

    It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease.

  4. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  5. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    It is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease.

  6. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    It has served as one of the lead compounds for the development of the synthetic compounds used today. … It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins.

  7. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment. … It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.

  8. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. … cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it

  9. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    It is being developed by Synta Pharmaceuticals.

  10. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007.